Strategic Partnerships Aortix is investigational and not available for sale, but Procyrion has actively pursued regulatory and reimbursement milestones (CMS codes, ICD-10-PCS), suggesting opportunities to position partnerships with hospitals, payers, and distributors once FDA clearance or broader access is achieved.

Targeted Markets Focus on high-impact cardio-renal care settings where cardiorenal syndrome and prevention of acute kidney injury are priorities; leverage recent clinical enrollments and pivotal IDE progress to approach academic medical centers and cardiology/nephrology programs.

Clinical Adoption With first-in-human success and ongoing IDE trials, there is a need for clinician education and trial-ready sites; engage key thought leaders and CICs at major cardiovascular institutes to drive clinical trial participation and future adoption.

Reimbursement Readiness Procyrion has secured reimbursement codes and hospital procedure coding, indicating a готов readiness to discuss post-market pathways; build collateral for hospital procurement, BAS, and payer conversations highlighting cost-benefit and CKD outcome improvements.

Funding & Growth Recent Series E funding and executive appointments signal financial momentum and customer-facing leadership growth; leverage this to approach strategic investors, potential distribution partners, and large hospital systems for co-development or exclusive distribution deals.